What Vima Therapeutics does

Vima Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing oral therapies for movement disorders, with a lead focus on isolated dystonia and Parkinson's disease. The company was founded in 2025 and incubated at Atlas Venture, launching from stealth in May 2025 with a $60 million Series A led by Atlas Venture and later extending the round to $100 million in March 2026 with Frazier Life Sciences joining existing investors Access Industries and Canaan Partners.

Vima's core asset is VIM0423, a potential first-in-class once-daily oral therapeutic that selectively targets muscarinic cholinergic receptors in the brain and is designed to improve tolerability over existing muscarinic approaches. The candidate was in-licensed under an exclusive worldwide agreement with Children's Mercy (Kansas City) covering methods and compositions of treating movement disorders with certain antimuscarinic compounds. VIM0423 has received FDA Fast Track designation for isolated dystonia and is currently in Phase 2 development: the Stride Dystonia Phase 2 trial dosed its first patient in March 2026, with a Parkinson's disease Phase 2 trial planned for mid-2026 and topline data from both expected in the first half of 2027.

The company is pre-revenue and does not yet have a commercial product. Its go-to-market motion is a traditional clinical-stage biotech model built around clinical trial execution, FDA engagement, and patient recruitment through ClinicalTrials.gov and a dedicated study website, with future revenue dependent on FDA approval and commercialization through prescription drug distribution channels. Customer segments are defined by indication rather than paying buyers: isolated dystonia patients (over 160,000 U.S. adults and children, with no FDA-approved oral therapy available) and Parkinson's disease patients (part of a movement-disorder population exceeding 1 million in the U.S.).

Name

Vima Therapeutics

Legal name

Vima Therapeutics

Website

https://vimatx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Vima Therapeutics is a clinical-stage Cambridge, MA biotech developing VIM0423, a first-in-class once-daily oral therapy targeting muscarinic receptors for isolated dystonia and Parkinson's disease, currently in Phase 2 trials.

Ownership category

akta.pro rank

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. Drug commercialization: Pre-revenue clinical-stage biotechnology company. Revenue will be generated through commercialization of VIM0423 upon FDA approval. Potential future revenue from additional pipeline candidates targeting movement disorders including Parkinson's disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Vima Therapeutics is developing VIM0423, a potential first-in-class once-daily oral therapy that selectively targets muscarinic cholinergic receptors in the brain. The drug is being advanced for the treatment of isolated dystonia (currently in Phase 2) and Parkinson's disease (Phase 2 planned mid-2026). The candidate is designed to maximize both efficacy and tolerability relative to existing muscarinic receptor-targeting approaches that are limited by central and peripheral tolerability issues.

Product overview

Vima Therapeutics is advancing VIM0423, a single lead therapeutic candidate - a potential first-in-class once-daily oral therapy targeting muscarinic cholinergic receptors in the brain. VIM0423 is being developed for the treatment of isolated dystonia and Parkinson's disease. The company has received FDA Fast Track designation for isolated dystonia and is currently conducting Phase 2 clinical trials for both indications, with topline data expected in the first half of 2027. VIM0423 was licensed from Children's Mercy for methods and compositions of treating movement disorders with certain antimuscarinic compounds.

Differentiator

Problem solved

Functional benefit

Products and services

• VIM0423 VIM0423 is a potential first-in-class once-daily oral therapy that selectively targets muscarinic cholinergic receptors in the brain. It is being developed for the treatment of isolated dystonia and Parkinson's disease, and has received FDA Fast Track designation for isolated dystonia.

Quantifiable outcome

• Phase 1: VIM0423 demonstrated favorable safety profile and was well-tolerated up to and exceeding target doses over 28 days in healthy volunteers and dystonia patients
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Children's MercycoreStrategic or Co-development PartnerExclusive worldwide license from Children's Mercy (nationally recognized, independent pediatric health system in Kansas City, Missouri) to methods and compositions of treating movement disorders with certain antimuscarinic compounds. This license provides Vima with IP rights for VIM0423.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Praxis Precision Medicines: Clinical-stage CNS therapeutics company focused on neurology and psychiatry; former employer of Vima founder/CEO Bernard Ravina (CMO) and overlapping investor base — directly comparable in clinical CNS drug development focus and stage.
• Cerevel Therapeutics: Clinical-stage neuroscience biotech developing small-molecule therapies across CNS indications — analogous in therapeutic modality (oral small molecule), clinical stage, and CNS focus to Vima's platform.
• Sage Therapeutics: CNS-focused specialty biotech developing novel small-molecule therapeutics for neurological and psychiatric disorders; comparable in therapeutic area, modality, and clinical-stage biotech profile.
• Intra-Cellular Therapies: CNS-focused pharmaceutical company with commercial-stage products for neurological/psychiatric indications (e.g., Caplyta); relevant comparable for small-molecule CNS strategy moving from clinical to commercial.
• Karuna Therapeutics: CNS specialty biotech developing novel muscarinic receptor-targeted therapies for schizophrenia and other CNS conditions — highly relevant given Vima's muscarinic mechanism and shared CNS specialty biotech positioning.

Broad incumbents

• Acadia Pharmaceuticals: Established CNS biopharmaceutical company with movement-disorder and neurology commercial products (e.g., Parkinson's psychosis) — comparable as a broader incumbent in the movement-disorder treatment space.
• Neurocrine Biosciences: Major commercial-stage neuroscience company with established movement-disorder franchises (e.g., tardive dyskinesia, Parkinson's) — directly relevant as both a competitor for movement-disorder share and a potential acquirer of late-clinical CNS assets.
• Supernus Pharmaceuticals: Commercial specialty CNS biopharmaceutical company with Parkinson's disease products (e.g., Gocovri for dyskinesia) — relevant broader incumbent competing for movement-disorder market share.
• Lundbeck: Global CNS pharmaceutical company with established neurology and movement-disorder product portfolio — comparable as a broader incumbent that could acquire or partner with a focused late-clinical CNS asset like Vima.

Emerging players

• Voyager Therapeutics: Clinical-stage gene therapy company focused on neurological diseases including Parkinson's; former employer of Vima's CEO and overlapping CNS/movement-disorder clinical development focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vima-therapeutics/about/?viewAsMember=true

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vima Therapeutics